CG-806 is primarily investigated for its potential therapeutic applications in cancer treatment, particularly chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). It functions as a small molecule inhibitor targeting Bruton's tyrosine kinase (BTK), a key enzyme involved in signaling pathways that promote cancer cell proliferation and survival. By inhibiting BTK, CG-806 helps slow or halt the growth of cancer cells, making it a promising option for treating these malignancies. Researchers are exploring its efficacy, with preclinical studies suggesting it may reduce tumor growth and improve outcomes. Its application remains under development, with ongoing clinical trials evaluating safety, tolerability, and effectiveness in human patients.